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Risk Factors for Venous Thromboembolism
Samuel Z. Goldhaber, MD
Boston, Massachusetts
Risk factors for venous thromboembolism (VTE) are often modifiable and overlap with risk factors for coronary
artery disease. Encouraging our patients to adopt a heart-healthy lifestyle by abstaining from cigarettes, main-
taining lean weight, limiting red meat intake, and controlling hypertension might lower the risk of pulmonary
embolism and deep vein thrombosis (DVT), although a cause-effect relationship has not been firmly established.
For hospitalized patients, guidelines have provided evidence-based strategies to identify patients at risk, such as
elderly persons and those with cancer, congestive heart failure, or chronic obstructive pulmonary disease or un-
dergoing major surgery. Most should receive pharmacological prophylaxis, which will minimize the risk of VTE.
Because approximately 3 of every 4 pulmonary embolism and DVT events occur outside the hospital setting,
patients should also be assessed for persistent high-risk of VTE at the time of hospital discharge. (J Am Coll
Cardiol 2010;56:1–7) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.057w
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wn 2008, Steven K. Galson, MD, MPH, issued the Surgeon
eneral’s Call to Action to Prevent Deep Vein Thrombosis
nd Pulmonary Embolism (1). The Surgeon General esti-
ates that, in the U.S. alone, 100,000 to 180,000 deaths
ccur annually because of venous thromboembolism (VTE).
TE and its complications place a substantial burden on the
.S. health care system (2). The sequelae of post-
hrombotic syndrome (3) and chronic thromboembolic
ulmonary hypertension (4,5) are sources of morbidity,
iminished quality of life, and loss in functional status.
There exists an impression that risk factors for deep
enous thrombosis (DVT) and pulmonary embolism (PE)
re quite different from risk factors for coronary artery
isease. In fact, we are learning that VTE is a cardiovascular
isease and that the risk factors for arterial and venous
hrombosis are similar. Many of the VTE risk factors might
e modifiable by adopting a “heart healthy lifestyle.” This
rovides the cardiologist the opportunity to engage patients
o help them reduce the risk of arterial thrombosis and
ossibly of VTE simultaneously.
Nonmodifiable risk factors such as being elderly or having
ancer can be readily identified. They provide an early
arning to the cardiovascular practitioner that additional
reventive measures will be necessary to avoid DVT and
E. Fortunately, well-established prophylaxis is available
nd based upon carefully performed trials.
rom Harvard Medical School, Venous Thromboembolism Research Group, Car-
iovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts. Dr.
oldhaber is a consultant for Sanofi-Aventis, Eisai, Bristol-Myers Squibb, and
edscape, and has received clinical research support from Sanofi-Aventis, Bristol-
yers Squibb, Boehringer Ingelheim, and Johnson & Johnson.w
Manuscript received May 29, 2009; revised manuscript received January 22, 2010,
ccepted January 25, 2010.For those patients who do suffer VTE, many will ask
hether it is safe to discontinue anticoagulation after a
ertain period of time. The optimal duration of anticoagu-
ation is one of the most vexing issues in VTE management.
owever, analysis of a patient’s risk factors for recurrence
ight assist in decision-making.
Too often, a review of risk factors centers on the
ospitalized patient. However, we must keep in mind that 3
f 4 VTE events occur outside of the hospital setting (6).
urthermore, there is a relationship between VTE that
ccurs in the community and previous hospital stay. Many
cute DVT and PE cases that occur at home can be linked
o a hospital stay or surgical procedure within the preceding
0 days (7). Thus, when conceptualizing risk factors for
TE, we should take into account the entire continuum of
are.
This review aims to put an end to “silo thinking” about
TE risk factors (Table 1). First, there is much overlap in
rterial and venous thrombosis risk factors. Second, proper
rophylaxis against VTE during and after hospital stay has
he potential to reduce markedly the frequency of VTE.
egistries
egistries provide an excellent starting point when studying
isk factors for VTE. The largest registry that enrolled only
atients with PE (and excluded patients with DVT alone) is
he ICOPER (International Cooperative Pulmonary Embo-
ism Registry) (8). Consecutive patients (n  2,454) were
egistered from 52 hospitals in 7 countries in Europe and
orth America. After exclusion of 61 patients in whom PE
as first discovered at autopsy, the mortality rate at 3 months
as 15%. Risk factors associated with an increased likelihood
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Risk Factors for VTE June 29, 2010:1–7of death included: age 75 years,
cancer, congestive heart failure,
and chronic obstructive pulmonary
disease (COPD).
The largest registry with both
PE and DVT patients is called
the RIETE (Registro Informati-
zado de la Enfermedad Trombo-
Embolica venosa) registry. Of
15,520 consecutive patients with
acute VTE, 6,264 had symptom-
atic nonmassive PE, and 248 had
symptomatic, massive PE. The
linical risk factors predicting death included immobiliza-
ion for neurological disease, age 75 years, and cancer (9).
The Longitudinal Investigation of Thromboembolism
tiology combined 2 cohorts representing different regions
f the U.S. The combined sample comprised 21,680 par-
icipants. The age-standardized incidence of first-time VTE
as 1.92/1,000 person-years. The 28-day case-fatality rate
as 11% after a first VTE episode. Of the cases, 48% were
diopathic and unprovoked, meaning that they were not
ssociated with preceding surgery, trauma, immobilization,
r cancer. Those with cancer-associated VTE had a higher
8-day case-fatality rate of 25% (10).
verlap of Venous and
rterial Thrombosis Risk Factors
randoni et al. (11) discovered an association between
symptomatic carotid artery atherosclerosis and DVT in a
ase-control study of unselected patients with DVT who did
ot have symptomatic atherosclerosis. Among Canadian
atients 20 to 39 years of age presenting with unprovoked
TE, the risk of subsequent myocardial infarction (MI)
ver the ensuing decade was 4-fold higher compared with
ontrol subjects (12). In a Danish registry of DVT patients,
he relative risk for MI was 1.60, and the relative risk for
troke was 2.19 at 1 year after the initial event (13). In a
.S. cohort of 304 subjects with VTE, 8 events (2.6%)
ccurred in the setting of MI (10). There seems to be a
elationship between markers of inflammation and venous
hrombosis, but proving a cause-effect relationship remains
lusive (14). The most convincing “bridge” between venous
nd arterial thrombosis is the JUPITER (Justification for
he Use of Statins in Prevention: an Intervention Trial
valuating Rosuvastatin) trial of 17,802 apparently healthy
en and women with elevated C-reactive protein levels.
hey received rosuvastatin 20 mg or its placebo for a median
f 2 years. The rosuvastatin group had a 43% reduction in
enous thromboembolic events compared with the control
roup (15).
To investigate risk factors for PE in women, the all
emale Nurses’ Health Study cohort was studied. There
ere 112,822 women 30 to 55 years of age at baseline who
Abbreviations
and Acronyms
COPD  chronic
obstructive pulmonary
disease
DVT  deep vein
thrombosis
MI  myocardial infarction
PE  pulmonary embolism
VTE  venous
thromboembolismere free of cardiovascular disease or cancer. With 16 years Vf follow-up, there were 1,619,770 person-years of follow-
p. Two hundred eighty new PE cases were reported,
ncluding 125 that were idiopathic and unprovoked (16).
Three major risk factors for PE were found: obesity,
igarette smoking, and hypertension. Women with a body
ass index29 kg/m2 had a relative risk of 2.9 for suffering
diopathic PE. The relative risk of idiopathic PE was 1.9 for
omen currently smoking 25 to 34 cigarettes/day and 3.3
or women smoking 35 or more cigarettes daily compared
ith never smokers. Hypertension had a relative risk of 1.9
or idiopathic PE. Data were similar for provoked PE
ssociated with preceding surgery, trauma, cancer, or im-
obilization.
Obesity was a risk factor for VTE in a case control study
n the Netherlands (17) and in a cohort study from the U.S.
ational Hospital Discharge Survey (18). In the American
tudy, obese women had a greater relative risk for DVT than
bese men, 2.75 versus 2.02.
Nutritional factors have received only scant attention as
isk factors for VTE. In a prospective study of 14,962 adults
ver 12 years, 197 noncancer-related VTEs were identified
19). A food frequency questionnaire assessed dietary intake
t baseline and at year 6. Eating fish at least once weekly was
ssociated with a 30% reduction in VTE incidence. The top
uintile of red meat eaters was twice as likely as the bottom
uintile to develop VTE. Those who ate an average of2.5
ervings/day of fruits and vegetables could lower their VTE
isk by at least 30%. Consumption of at least 4 servings of
ruit and vegetables daily and at least 1 serving of fish weekly
as associated with the lowest incidence of VTE.
Stress has been linked to coronary heart disease but has
arely been studied with respect to VTE risk. In a cohort of
,958 Swedish men with persistent stress followed for up to
8 years and assessed by questionnaire, two-thirds had a
igher rate of PE compared with men who had low stress
evels (20). Thus, psychosocial stress might precipitate PE.
Ageno et al. (21) performed a meta-analysis of 63,552
atients from 21 case-control and cohort studies to assess
he association between cardiovascular risk factors and
TE. Compared with control subjects, the odds ratio for
TE risk was: 2.3 for obesity, 1.5 for hypertension, 1.4 for
iabetes mellitus, and 1.2 for hypercholesterolemia.
The association between classic coronary heart disease
isk factors and VTE risk factors provides a starting point
or individual screening, risk factor modification, and pre-
ltering Silo Thinking About VTE Risk FactorsTable 1 Altering Silo Thinking About VTE Risk Factors
1. VTE and arterial thrombosis risk factors are similar. Counseling patients to
modify risk factors might reduce the likelihood of both VTE and myocardial
infarction.
2. VTE risk factors persist at home and in skilled nursing facilities. When
discharging a patient from the hospital, consider ordering prophylactic
measures that continue after hospital discharge.TE  venous thromboembolism.
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June 29, 2010:1–7 Risk Factors for VTEention. Practitioners can counsel patients with the aim of
educing the frequency of both MI and VTE (Table 2).
isk Factors Among Hospitalized Patients
ultiple scoring systems are available to identify hospital-
zed patients at high risk for VTE. Those patients at
oderate or high risk warrant prophylaxis, usually with low,
xed preventive doses of anticoagulant drugs such as low
olecular weight heparin, unfractionated heparin, or
ondaparinux.
The high death rate from PE, which exceeds the death
ate from acute MI, emphasizes the need for improved
reventive efforts. Failure to institute prophylaxis among
ospitalized patients is a much bigger problem with Medical
ervice patients than Surgical Service patients. The number
f patients at risk in the U.S. annually is staggering: more
han 7 million Medical Service and 3 million Surgical
ervice patients (22).
The eighth edition of the American College of Chest
hysicians guidelines (23) declares that “every hospital
hould develop a formal strategy to prevent VTE.” A VTE
rophylaxis is effective and reduces by more than one-half
he frequency of PE and DVT (24). Nevertheless, it
ontinues to be underused throughout the world (25).
Electronic alerts to physicians whose patients are at high
isk but who are not receiving prophylaxis reduce symptom-
tic VTE by more than 40% (26) and maintain effectiveness
ver time (27). “Human” alerts, in which a hospital staff
ember contacts the responsible physician when a high-risk
atient is not receiving prophylaxis, can reduce symptomatic
TE by more than 20% (28). Prophylaxis is also cost-
ffective (29).
Among patients undergoing major surgery, we found low
ates of prophylaxis and high rates of inferior vena cava filter
nsertion in a prospective registry of 5,451 patients with
ltrasound confirmed DVT from 183 hospitals in the U.S.
mong surgical patients who developed DVT, some form
f prophylaxis had been used in only 44%. Once diagnosed
ith DVT, 20% of surgical patients received permanent
nferior vena cava filters (30).
This same registry found that, among patients initially
ospitalized for conditions other than VTE, medical pa-
ients received prophylaxis less often than nonmedical pa-
ients (25% vs. 54%, respectively; p  0.0001) (31). Under-
se of VTE prophylaxis extended to both pharmacological
otential Modification of VTE Risk FactorsTable 2 Potential Modification of VTE Risk Factors
1. Obesity: nutritional counseling, exercise, medication, bariatric surgery
2. Cigarettes: cigarette cessation programs, medication, hypnosis
3. Hypertension: exercise, weight loss, medication
4. Diabetes: exercise, weight loss, medication
5. High cholesterol: exercise, weight loss, medication
6. Nutrition: counseling, education
7. Stress: counseling, medicationsTE  venous thromboembolism.nd mechanical modalities. In addition, medical patients
eveloped PE more often (22%) than nonmedical patients
15%) (p  0.0001).
Hospitalized patients with cancer had twice the incidence
f DVT and PE as patients without cancer (32), on the basis
f the National Hospital Discharge Survey. The highest
ncidence of VTE was in patients with pancreatic cancer,
.1%. In the California Cancer Registry, which was linked
o the California Patient Discharge Data Set, the highest
ncidence of VTE in cancer patients occurred during the
rst year of follow-up (33). The number of VTE events/100
atient-years was: 20 for metastatic pancreatic cancer, 11 for
tomach cancer, 8 for bladder cancer, 6 for uterine and renal
ancer, and 5 for lung cancer.
What is less clear is the likelihood of a subsequent cancer
iagnosis in a patient with newly diagnosed VTE. In a
ohort of 1,852 patients with VTE who were followed for 4
ears, 105 (5.7%) were diagnosed with new cancer (24). The
isk more than doubled for patients who had presented with
diopathic and unprovoked VTE. The annualized risk for
ew cancer was 1.3/100 person-years of follow-up.
Congestive heart failure was associated with VTE in the
ational Hospital Discharge Survey (34). The relative risk
or PE in patients with congestive heart failure was 2.1
ompared with patients with no congestive heart failure. For
VT, the relative risk was 1.2. In a DVT registry of 5,451
atients with ultrasound confirmed venous thrombosis (35),
ongestive heart failure patients had higher medical acuity
ith more comorbid diseases such as stroke and pneumonia,
ore frequent risk factors such as immobilization, and a
ower rate of VTE prophylaxis than patients without con-
estive heart failure. The risk of VTE is low after uncom-
licated MI.
The relationship between acute exacerbations of COPD
nd the prevalence of PE has been uncertain. Therefore,
izkallah et al. (36) undertook a meta-analysis. They found
hat the overall prevalence of PE in this population was
0%, but the prevalence was higher—25%—among hospi-
alized patients. Thus, the diagnosis of PE should be
onsidered in patients with COPD exacerbations severe
nough to warrant hospital stay. Similar results were found
n a case series of patients in France with unexplained
xacerbations of COPD (37).
A myth abounds that patients with chronic kidney disease
re not susceptible to VTE because qualitatively defective
latelets provide protection against thrombosis. However, a
arge retrospective cohort study refutes this premise. Two
undred ninety-eight consecutive patients with nephrotic syn-
rome were followed for an average of 11 years (38). During
he first 6 months of follow-up, the incidence of symptomatic
TE was 9.8%. These patients also had a 6-month incident
ate of 5.5% for arterial thromboembolism.
The bottom line is that, among hospitalized patients,
ertain populations deserve special vigilance, because they
re especially susceptible (Table 3). They might already have
uffered occult VTE.
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Risk Factors for VTE June 29, 2010:1–7isk Factors for Recurrent VTE
ertain clinical risk factors are associated with recurrent
TE despite anticoagulation (Table 4). A cohort study of
73 patients found that 3.0% of patients suffered recurrence
espite anticoagulation and that most (79%) recurrences
ere fatal. Risk factors for recurrence despite anticoagula-
ion included: immobilization, cancer, or COPD (39). A
ommon clinical problem is deciding whether to prescribe
ime-limited versus indefinite-duration anticoagulation.
hen anticoagulation is discontinued, the risk of recurrence
s higher among men than women (40,41). Other risk
actors for recurrence include elevated body mass index (42)
nd low levels of high-density lipoprotein cholesterol (43).
atients who initially present with symptomatic PE rather
han symptomatic DVT also have a higher risk of recurrence
44). Two laboratory coagulation tests have been proposed
or use after discontinuation of anticoagulation to predict
ossible recurrence: D-dimer (45) and thrombin generation
46). However, there is insufficient experience with these
ests to recommend them as part of the decision-making
rocess for prescribing indefinite versus time-limited
herapy.
The most recent approach to minimizing recurrent VTE
s the proposal of flexible dosing rather than traditional fixed
osing (either time-limited or indefinite-duration). Pran-
oni et al. (47) carried out a randomized trial of 538 patients
ith initial DVT. They did serial venous ultrasound exam-
nations to determine whether they could lower the recur-
ence rate with ultrasonography-guided duration of antico-
gulation. In the flexible dosing group, patients with
ecanalized veins were assigned brief durations of anticoag-
lation, whereas nonrecanalized patients received prolonged
ourses of anticoagulation. They found that tailoring the
uration of anticoagulation on the basis of ultrasonography
educed the rate of recurrent VTE. For now, however, the
vidence favors adhering to current guidelines with fixed,
ime-limited anticoagulation for provoked VTE and indef-
nite duration anticoagulation for idiopathic VTE (48).
enetics and the Thrombophilia Workup
he 2 most common genetic risk factors for VTE are factor
Leiden and the prothrombin gene mutation. The most
ommon acquired (nongenetic) cause is antiphospholipid
ntibody syndrome. Although the genetic risk factors in-
rease the likelihood of an initial VTE, they have little
ospitalized Patients Especially Susceptible to VTETable 3 Hospitalized Patients Especially Susceptible to VTE
Major surgery
Cancer
Congestive heart failure
Chronic obstructive pulmonary disease
Chronic kidney disease, especially nephrotic syndrome
TE  venous thromboembolism.mpact on the risk of recurrent VTE. Heterozygous factor V Deiden triples the risk of an initial VTE, and homozygous
actor V Leiden increases the risk approximately 15- to
0-fold (49). The most important predictor of recurrent
TE after discontinuation of anticoagulation is an initial
vent that is idiopathic and unprovoked (50,51).
Elucidating genetic predisposition to VTE is a complex
ask. Among 304 individuals who developed VTE while
articipating in the Physicians’ Health Study, several can-
idate gene polymorphisms were identified that were inde-
endently associated with risk of incident VTE. These
andidate genes include polymorphisms that mediate in-
ammation and metabolize lipids (52). Many additional
ingle-nucleotide polymorphisms associated with VTE have
een identified (53,54).
Thrombophilia workups are expensive and usually add
ittle to patient management. In general, I would not change
he duration of anticoagulation on the basis of the results of
esting. The most frequent exception is the finding of
levations in anticardiolipin antibodies. In patients with
igh anticardiolipin antibody levels who have suffered a
hrombotic event, I would consider indefinite duration
nticoagulation. Other aggressive thrombophilias include
omozygous factor V Leiden, homozygous prothrombin
ene mutation, double heterozygote mutations, protein C,
rotein S, and antithrombin deficiency. I do believe that
hrombophilia workups can often satisfy the curiosity of
atients, families, and referring physicians who ask whether
here was a special predisposition to thrombosis. I usually
rder a “mini thrombophilia workup” that is not influenced
y concomitant anticoagulation (Table 5). Novel thrombo-
hilia tests are being developed that focus on the genetics
nd biologic effects of thrombosis (55).
ong-Haul Air Travel
ong-haul air travel is possibly the most common risk factor
or VTE that is featured in the popular press. However, it is
ery rare. At Charles de Gaulle Airport in Paris, the
ncidence of PE was 4.8 cases/million for those traveling
ore than 10,000 km, compared with 1.5 cases/million for
hose traveling 5,000 km (56). An overview of travel-
elated VTE found a 2.8-fold higher rate of VTE in
isk Factors for Recurrent VTETable 4 Risk Factors for Recurrent VTE
While taking anticoagulant drugs
Immobilization
Cancer
Chronic obstructive pulmonary disease
After anticoagulant drugs are discontinued
Male sex
Overweight, obesity
Low high-density lipoprotein cholesterol
Presenting with symptoms of pulmonary embolism
(rather than symptoms of DVT)
Lack of recanalization of DVT on venous ultrasound examinationVT  deep vein thrombosis; VTE  venous thromboembolism.
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June 29, 2010:1–7 Risk Factors for VTEravelers than in control subjects. There was a dose-response
elationship of 18% higher risk for each 2-hour incremental
ncrease in travel duration (57). The American College of
hest Physicians guidelines recommend for high-risk trav-
lers, such as those with prior VTE, graduated compression
tockings or a single prophylactic dose of low molecular
eight heparin injected before departure, along with com-
on sense measures applicable to all travelers: avoidance of
onstrictive clothing, ensuring adequate hydration, and
ndertaking periodic calf muscle contraction (23).
ommunity-Acquired VTE
isk factor evaluation is important outside acute care
ospital settings (Table 6). In a community-based study in
estern France, two-thirds of acute VTE events occurred at
ome. And the incidence of VTE increased markedly with
ge (58). In a separate French case-control study of non-
ospitalized patients, the most common risk factors for
TE were: a history of prior VTE, venous insufficiency,
regnancy, trauma, frailty, and immobility (59). In Olmsted
ounty, Minnesota, a population-based case-control study
ound that independent risk factors for VTE included:
urgery, trauma, hospital stay or placement in a nursing
ome, and cancer (60).
Especially intriguing are the data emerging from the
orcester Venous Thromboembolism Study. Three-
uarters of VTE patients suffered their event in the outpa-
ient setting. Within the preceding 3 months, 23% had
ndergone surgery, and 36% had been hospitalized. Among
hose patients, two-thirds experienced VTE within 1 month
f hospital discharge. Major risk factors included cancer and
rior VTE (7). More than one-half of VTE events occurred
n subjects 65 years of age or older (61). Thus, in Worcester,
ailure to prophylax during hospital stay was associated with
he occurrence of outpatient DVT and PE.
omen’s Health
regnancy. In a U.S. nationwide inpatient sample, the
TE rate was 1.72/1,000 deliveries, with 1.1 deaths/
00,000. The risk of VTE was 38% higher for women 35
ears of age and older and 64% higher for black women.
hrombophilia was the most important risk factor (62).
uring pregnancy, the risk of VTE begins in the first
rimester (63). In a Mayo Clinic study, the highest risk
eriod seemed to be post-partum (64).
Hypercoagulability of pregnancy probably evolved to
rotect women from hemorrhage at the time of childbirth
Mini” Thrombophilia WorkupTable 5 “Mini” Thrombophilia Workup
Factor V Leiden
Prothrombin gene mutation
Anticardiolipin antibodies65). The most important thrombophilias are: factor V Veiden, prothrombin gene mutation, anticardiolipin anti-
ody elevation, antithrombin deficiency, and protein C and
deficiencies. However, routine thrombophilia screening is
ot considered cost-effective (66).
ral contraceptives. Most oral contraceptives combine an
strogen and a progestin. At least 10 million women in the
.S. and 100 million women worldwide use combination
ral contraceptives. The risk of VTE is increased by a factor
f 3 to 4 among current users. In addition, the risk seems to
ouble for formulations containing desogestrel or gesto-
ene, known as “third-generation” progestins (67,68).
hether women at high risk of VTE should undergo
hrombophilia testing before deciding to take oral contra-
eption is controversial.
ost-menopausal hormone therapy. In the Heart and
strogen/progestin Replacement Study (69) and in a meta-
nalysis (70), post-menopausal estrogen replacement was
ssociated with an increased risk of VTE. The magnitude of
isk was double to triple the baseline likelihood of VTE.
usceptibility to DVT or PE seemed to be highest during
he first year of hormone use.
ediatrics
enous thromboembolism in children has received little
ttention. Most VTE affects the upper extremity and is
ssociated with in-dwelling central venous catheters (71,72).
he highest incidence is during the neonatal period, fol-
owed by another peak in adolescence. Teenage girls have
wice the rate of VTE as teenage boys, probably due to use
f oral contraceptives and pregnancy (73).
onclusions
ur goal is to make VTE a rare disease. Careful attention to
isk factors is the key to achieving this objective. Until now,
isk factors have focused on hospitalized patients to deter-
ine whether they should receive anticoagulant or mechan-
cal prophylaxis. The tendency has been to highlight general
urgery, immobilization, congestive heart failure, COPD,
nd a history of prior VTE.
We should now consider additional lifestyle risk factors
hat patients and their health care providers can modify.
hese include “cardiac” risk factors such as cigarette smok-
ng, overweight, metabolic syndrome, hypertension, high
ed meat consumption, and hyperlipidemia. Risk factor
isk Factors for VTE in the CommunityTable 6 Risk Factors for VTE in the Community
Advancing age
Cancer
Prior VTE
Venous insufficiency
Pregnancy
Trauma
Frailty and immobilityTE  venous thromboembolism.
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Risk Factors for VTE June 29, 2010:1–7odification might reduce the likelihood of DVT or PE.
e must also include the community into our risk factor
nalysis. Many community-acquired VTE events are due to
nadequate VTE prophylaxis during a recent prior hospital
tay or surgical procedure. This link between hospital stay
nd community VTE requires that we assess the need for
rophylaxis at the time of hospital discharge.
New onset DVT or PE in the community that is not
elated to recent hospital stay might be due to a modifiable
cardiac” risk factor. Therefore, when we counsel our cardiac
atients to stop smoking cigarettes, we can tell them that
moking cessation will lower the risk of MI, lung cancer,
nd possibly VTE.
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